Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 1.27M USD.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 1.27M USD.
Infravalorada
El PE más reciente de la empresa es -19.74, en un rango percentil bajo de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 32.64M acciones, lo que supone un aumento del 8.67% con respecto al trimestre anterior.
En posesión de Paul Tudor Jones
El inversor estrella Paul Tudor Jones posee 14.94K acciones de este valor.